Notable
Vactosertib in Adolescents and · Recurrent, Refractory or Progressive Osteosarcoma
Primary completion pushed from Sep 2025 to Dec 2027
Also in this update: Enrollment increased: 48 → 78 participants; Trial sites expanded: 3 → 7 locations
MedPacto, Inc.Phase 1/2 NCT05588648 Registry history of NCT05588648 on ClinicalTrials.gov (opens the registry)